Organon & Co. (NYSE:OGN) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen lowered shares of Organon & Co. (NYSE:OGN) from a buy rating to a hold rating in a research report released on Saturday morning.

A number of other research analysts also recently commented on OGN. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organon & Co. in a report on Wednesday, October 8th. JPMorgan Chase & Co. lowered their price objective on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a research note on Tuesday, November 11th. Barclays assumed coverage on Organon & Co. in a report on Tuesday, December 9th. They issued an “underweight” rating and a $7.50 target price for the company. Morgan Stanley decreased their price target on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 11th. Finally, Piper Sandler downgraded Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price target for the company. in a research report on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat, Organon & Co. currently has an average rating of “Reduce” and an average target price of $8.38.

Organon & Co. Trading Down 1.0%

OGN stock opened at $8.51 on Friday. The firm has a fifty day moving average price of $7.80 and a 200 day moving average price of $8.72. Organon & Co. has a fifty-two week low of $6.18 and a fifty-two week high of $17.23. The firm has a market cap of $2.21 billion, a PE ratio of 4.43, a price-to-earnings-growth ratio of 1.84 and a beta of 0.58. The company has a debt-to-equity ratio of 9.69, a quick ratio of 1.20 and a current ratio of 1.75.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Monday, November 10th. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.08. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the firm earned $1.38 earnings per share. Sell-side analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 11th. Stockholders of record on Thursday, November 20th were given a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Thursday, November 20th. Organon & Co.’s dividend payout ratio (DPR) is 4.17%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its position in Organon & Co. by 22.4% in the 2nd quarter. GAMMA Investing LLC now owns 5,645 shares of the company’s stock valued at $55,000 after buying an additional 1,034 shares during the period. Maryland State Retirement & Pension System raised its stake in shares of Organon & Co. by 1.4% during the second quarter. Maryland State Retirement & Pension System now owns 88,420 shares of the company’s stock valued at $856,000 after acquiring an additional 1,195 shares in the last quarter. Rexford Capital Inc. raised its stake in shares of Organon & Co. by 14.9% during the third quarter. Rexford Capital Inc. now owns 11,380 shares of the company’s stock valued at $122,000 after acquiring an additional 1,480 shares in the last quarter. Amalgamated Bank boosted its holdings in shares of Organon & Co. by 1.9% in the third quarter. Amalgamated Bank now owns 79,805 shares of the company’s stock valued at $852,000 after purchasing an additional 1,514 shares during the period. Finally, State of Alaska Department of Revenue grew its stake in Organon & Co. by 0.6% in the fourth quarter. State of Alaska Department of Revenue now owns 278,379 shares of the company’s stock worth $1,995,000 after purchasing an additional 1,570 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.